Annals of the New York Academy of Sciences

Cover image for Annals of the New York Academy of Sciences

May 1995

Volume 754 Combined Vaccines and Simultaneous Administration: Current Issues and Perspectives

Pages xi–xii, 1–388

    1. Overview—Combination Vaccines and Simultaneous Administration: Past, Present, and Future (pages xi–xii)

      KAREN L. GOLDENTHAL, DRUSILLA L. BURNS, LORIS D. McVITTIE, BENJAMIN P. LEWIS JR. and JIM C. WILLIAMS

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44430.x

  1. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. FDA Perspective on Regulatory Issues in Vaccine Development (pages 10–16)

      BASCOM F. ANTHONY

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44432.x

    2. Strategies for Developing Combination Vaccines (pages 17–22)

      RONALD J. SALDARINI

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44433.x

    3. Manufacturing Issues for Multivalent Vaccines (pages 23–26)

      ARTHUR Y. ELLIOTT

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44434.x

    4. Combination Vaccines: Regulatory Issues (pages 27–34)

      D. K. McCLINTOCK

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44435.x

  2. Part II. Advances in the Development of Conjugate and Combination Vaccines

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. Determinant Flanking Regions and the Design of Appropriate Vaccines (pages 48–56)

      LUIS SOARES, HONGKUI DENG, IQBAL S. GREWAL, VIPIN KUMAR, ALEXANDER MILLER, KAMAL D. MOUDGIL, MARK PALMER and ELI E. SERCARZ

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44437.x

    2. Selection of Carrier and B Cell Protectope Sequences for Vaccines (pages 57–67)

      HOWARD M. ETLINGER

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44438.x

    3. Prevention of Systemic Infections Caused by Group B Streptococcus and Staphylococcus aureus by Multivalent Polysaccharide-Protein Conjugate Vaccines (pages 68–81)

      JOHN B. ROBBINS, RACHEL SCHNEERSON, WILLIE F. VANN, DOLORES A. BRYLA and ALI FATTOM

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44439.x

    4. Immune Responses to Pertussis Vaccines Concurrently Administered with Viral Vaccines (pages 89–96)

      SCOTT A. HALPERIN, BRIAN J. EASTWOOD and JOANNE M. LANGLEY

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44441.x

  3. Part III. New Approaches in Design and Use of Vaccine Adjuvants

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. Vaccine Strategies: Targeting Helper T Cell Responses (pages 126–137)

      BASIL GOLDING and DOROTHY E. SCOTT

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44445.x

    2. The Role of sIgA + B Cells in Oral Immunity (pages 138–142)

      ROLF O. EHRHARDT and WARREN STROBER

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44446.x

    3. Immunologic Adjuvants for Modern Vaccine Formulations (pages 153–160)

      FREDERICK R. VOGEL

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44448.x

  4. Part IV. New Antigen Delivery Systems: Construction and Use

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety (pages 187–201)

      D. R. MILICH, D. L. PETERSON, J. ZHENG, J. L. HUGHES, R. WIRTZ and F. SCHÖDEL

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44451.x

    2. Yeast Retrotransposon Particles as Antigen Delivery Systems (pages 202–213)

      ALAN J. KINGSMAN, NIGEL R. BURNS, GUY T. LAYTON and SALLY E. ADAMS

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44452.x

    3. Progress on Development of the Live BCG Recombinant Vaccine Vehicle for Combined Vaccine Delivery (pages 214–221)

      MARK S. HANSON, CLAUDIA VIGIL LAPCEVICH and SHIRLEY L. HAUN

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44453.x

    4. Live Attenuated Vaccinia and Other Poxviruses as Delivery Systems: Public Health Issues (pages 222–233)

      MARION E. PERKUS, JILL TAYLOR, JAMES TARTAGLIA, STEVEN PINCUS, ELIZABETH B. KAUFFMAN, JOHN A. TINE and ENZO PAOLETTI

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44454.x

  5. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. Issues in Design of Clinical Trials of Combination Vaccines (pages 234–240)

      MICHAEL D. DECKER and KATHRYN M. EDWARDS

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44455.x

    2. Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination (pages 289–299)

      ROLAND W. SUTTER, MARK A. PALLANSCH, LEIGH A. SAWYER, STEPHEN L. COCHI and STEPHEN C. HADLER

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44462.x

    3. Similarity/Equivalence Trials for Combination Vaccines (pages 321–327)

      WILLIAM C. BLACKWELDER

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44465.x

  6. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. Combination Live Enteric Virus Vaccines (pages 347–350)

      SAMUEL L. KATZ

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44467.x

    2. Combination Live Respiratory Virus Vaccines (pages 351–355)

      MARY LOU CLEMENTS

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44468.x

    3. Surrogate Serologic Tests for the Prediction of Pertussis Vaccine Efficacy (pages 359–363)

      JAMES D. CHERRY, ULRICH HEININGER, PETER D. CHRISTENSON, THOMAS ECKHARDT, SUZANNE LAUSSUCQ, JILL G. HACKELL, JOSEPH R. MEZZATESTA and KLEMENS STEHR

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44470.x

    4. Vaccine Licensure: A Proposal to Meet Changing Needs (pages 368–375)

      FREDERICK C. ROBBINS and EDWARD A. MORTIMER JR.

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44472.x

  7. Comprehensive Evaluation of Vaccine Safety

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. Utility of Large-linked Databases in Vaccine Safety, Particularly in Distinguishing Independent and Synergistic Effects (page 377)

      STEVEN G. F. WASSILAK, JOHN W. GLASSER, ROBERT T. CHEN, STEPHEN C. HADLER and THE VACCINE SAFETY DAIALINK INVESTIGATORS

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44473.x

  8. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. Combination Vaccines: Some Practical Considerations (pages 383–387)

      ROBERT S. DAUM, ANJALI JAIN and KAREN P. GOLDSTEIN

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44474.x

  9. Summary

    1. Top of page
    2. Part I. The Interface between Vaccine Initiatives, New TechnologieS, and Vaccine Development
    3. Part II. Advances in the Development of Conjugate and Combination Vaccines
    4. Part III. New Approaches in Design and Use of Vaccine Adjuvants
    5. Part IV. New Antigen Delivery Systems: Construction and Use
    6. Part V. Considerations for the Evaluation of Combination Vaccines: Clinical Design, Efficacy, and Statistical Issues
    7. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    8. Comprehensive Evaluation of Vaccine Safety
    9. Part VI. Clinical Considerations for the Evaluation of Combination Vaccines
    10. Summary
    1. A Perspective on Issues Relating to Future Vaccines (page 388)

      BARRY R. BLOOM

      Version of Record online: 17 DEC 2006 | DOI: 10.1111/j.1749-6632.1995.tb44475.x

SEARCH

SEARCH BY CITATION